BioWorld Asia

Feb. 7, 2007

Push By AstraZeneca Includes COPD Deal Worth Up To $500M

LONDON - AstraZeneca plc went through a hyperactive round last week of licensing and acquisitions, sealing deals worth $650 million. (BioWorld International) Read More

Circassia Raises £6M To Move Its Allergenic Products Ahead

Study Confirms Prion Protein As Therapeutic Target In CJD

ScanBalt Promoting Baltic Biotechnology Cooperation

AstraZeneca Buys Antiviral Firm Arrow For $150M Cash

Jerini Extends Pact With Baxter For New Hemophilia Drugs

NicOx Details Offer To Raise €130M

No Abstract Read More

Europe Moves Ahead On Advanced Therapy Rules

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 30, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 30, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...